U.S. patent application number 15/140132 was filed with the patent office on 2016-08-18 for process for preparing a pharmaceutical formulation of contrast agents.
This patent application is currently assigned to GUERBET. The applicant listed for this patent is GUERBET. Invention is credited to Vincent BARBOTIN, Bruno BONNEMAIN, Claire COROT, Dominique MEYER, Marc PORT.
Application Number | 20160235868 15/140132 |
Document ID | / |
Family ID | 40955314 |
Filed Date | 2016-08-18 |
United States Patent
Application |
20160235868 |
Kind Code |
A1 |
MEYER; Dominique ; et
al. |
August 18, 2016 |
PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST
AGENTS
Abstract
The invention relates to a process for preparing a liquid
pharmaceutical formulation containing a complex of macrocyclic
chelate with a lanthanide and a mol/mol amount offree macrocyclic
chelate of between 0.002% and 0.4%, advantageously between 0.02%
and 0.3% and very advantageously between 0.025% and 0.25%, the
macrocyclic chelate advantageously being chosen from DOTA, NOTA,
DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA,
the said process comprising the following successive steps: b)
preparation of a liquid pharmaceutical composition containing,
firstly, the complex of macrocyclic chelate with a lanthanide, and,
secondly, free macrocyclic chelate and/or free lanthanide; c)
measurement in the pharmaceutical formulation obtained in step b)
of the concentration of free macrocyclic chelate C.sub.ch1 and/or
of free lanthanide C.sub.lan1; d) adjustment of C.sub.ch1 and/or of
C.sub.lan1 so as to obtain C.sub.ch1=C.sub.t ch1 and C.sub.lan1=0,
wherein c.sub.t ch1 is the target concentration of free macrocyclic
chelate in the final liquid pharmaceutical formulation.
Inventors: |
MEYER; Dominique; (La
Rochelle, FR) ; COROT; Claire; (Lyon, FR) ;
PORT; Marc; (Deuil La Barre, FR) ; BARBOTIN;
Vincent; (Montmorency, FR) ; BONNEMAIN; Bruno;
(Villeparisis, FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
GUERBET |
Villepinte |
|
FR |
|
|
Assignee: |
GUERBET
Villepinte
FR
|
Family ID: |
40955314 |
Appl. No.: |
15/140132 |
Filed: |
April 27, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12918259 |
Feb 8, 2011 |
|
|
|
PCT/EP2009/051937 |
Feb 18, 2009 |
|
|
|
15140132 |
|
|
|
|
12155997 |
Jun 12, 2008 |
|
|
|
12918259 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 45/06 20130101;
A61K 47/18 20130101; A61K 9/0019 20130101; A61K 49/106 20130101;
G01N 33/15 20130101; A61K 31/28 20130101; A61K 49/108 20130101;
A61P 43/00 20180101 |
International
Class: |
A61K 49/10 20060101
A61K049/10; A61K 9/00 20060101 A61K009/00 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 19, 2008 |
FR |
0851055 |
Apr 17, 2008 |
EP |
08154745.7 |
Claims
1-37. (canceled)
38. Industrial process for preparing a liquid pharmaceutical
formulation containing a complex of macrocyclic chelate with a
lanthanide and a mol/mol amount of free macrocyclic chelate of
between 0.002% and 0.4%, said process comprising the following
successive steps: b) preparing a liquid pharmaceutical formulation
containing a complex of macrocyclic chelate with a lanthanide, and:
free macrocyclic chelate, and/or free lanthanide; said step b)
consisting in the preparation of a solid complex
[chelate-lanthanide] and in the dissolution of the said complex in
water; c) measuring, in a sample of the liquid pharmaceutical
formulation obtained in step (b), C.sub.ch 1, the concentration of
free macrocyclic chelate C.sub.ch 1 and/or of free lanthanide
C.sub.lan 1; d) adjusting C.sub.ch 1 and/or C.sub.lan 1 in the
liquid pharmaceutical formulation by adding to the liquid
pharmaceutical formulation obtained in step b): if C.sub.lan 1>0
and/or C.sub.ch 1<C.sub.t ch 1, free macrocyclic chelate, if
C.sub.lan 1=0 and C.sub.ch 1>C.sub.t ch 1, free lanthanide, so
as to obtain C.sub.ch 1=C.sub.t ch 1 and C.sub.lan 1=0, with
C.sub.t ch 1 representing the target concentration of the free
macrocyclic chelate in the final liquid pharmaceutical formulation,
C.sub.t ch 1 being selected in the range of between 0.002% and 0.4%
mol/mol; wherein the amount of free macrocyclic chelate in the
final liquid pharmaceutical formulation corresponds to the
proportion of free macrocyclic chelate relative to the amount of
complexed macrocyclic chelate DOTA-Gd in the final liquid
pharmaceutical formulation in mol/mol, wherein the macrocyclic
chelate is DOTA and the lanthanide is gadolinium, and wherein the
operating steps b) and d) of the process occur in the same
reactor.
39. The process of claim 38, wherein the mol/mol amount of free
macrocyclic chelate of between 0.025% and 0.25%.
40. The process of claim 38, wherein the liquid pharmaceutical
formulation is a liquid pharmaceutical formulation of the meglumine
salt of a DOTA-gadolinium complex.
41. The process of claim 40, wherein the adjustment step (d)
comprises at the end a step of adjustment of the pH and of the
volume.
42. The process of claim 41, wherein the pH is adjusted with
meglumine.
43. The process of claim 38, wherein step (b) is carried out at a
temperature of between 60.degree. C. and 100.degree. C.
44. The process of claim 38, wherein step (b) is carried out at
80.degree. C.
45. The process of claim 38, wherein the preparation of the said
solid complex involves at least one treatment step chosen from
filtration, concentration, crystallization, drying and spraying,
for obtaining the appropriate physicochemical characteristics in
terms of solubility and purity.
46. The process of claim 38, wherein any calcium present in the
final liquid pharmaceutical formulation is present in an amount of
less than 50 ppm.
47. The process of claim 46, wherein the amount of calcium present
in the final liquid pharmaceutical formulation is less than 20
ppm.
48. The process of claim 47, wherein the amount of calcium present
in the final liquid pharmaceutical formulation is less than 5
ppm.
49. The process of claim 46, wherein the liquid pharmaceutical
formulation is prepared from ingredients including chelate powder,
water and meglumine, and wherein the amount of calcium in the
ingredients used to prepare the final liquid pharmaceutical
formulation is less than 50 ppm.
50. The process of claim 46, wherein it comprises, before step (c),
an intermediate step (b2) of measuring the amount of calcium in the
obtained solution, and removing any excess calcium in order to
obtain an amount of less than 50 ppm in said solution.
51. The process of claim 38, wherein it comprises an additional
step (e) of checking C.sub.ch 1 and C.sub.lan 1.
52. The process of claim 38, wherein step (b) is carried out at a
temperature of between 60.degree. C. and 100.degree. C. and in that
the liquid pharmaceutical formulation is then cooled before the
adjustment step (d).
53. The process of claim 38, wherein gadolinium is added as
gadolinium oxide in step (b), and where appropriate in step
(d).
54. The process of claim 38, wherein the liquid pharmaceutical
formulation is an injectable solution.
55. The process of claim 38, wherein step (c) is carried out at pH
7.
Description
[0001] The invention relates to pharmaceutical formulations of
contrast agents, in particular of complexes of chelates with
paramagnetic metal ions, especially for magnetic resonance imaging,
and to industrially efficient processes for obtaining these
formulations.
[0002] Many contrast agents based on complexes of chelates with
lanthanides (paramagnetic metal), in particular with gadolinium,
are known, and are described, for example, in document U.S. Pat.
No. 4,647,447. Several products are marketed, especially based on
macrocyclic chelates such as DOTA gadoterate
(1,4,7,10-tetraazacyclo-dodecane-N,N',N'',N'''-tetraacetic acid)
and gadoteridol HPDO3A, and linear chelates such as DTPA
(diethylenetriaminepentaacetic acid) and DTPA-BMA
(gadodiamide).
[0003] In the body, the complexes of chelates with lanthanide are
in a situation of chemical equilibrium, which may lead to a risk of
undesired release of the lanthanide, and more especially of
gadolinium. A person skilled in the art is thus led to seek
technical solutions that limit this risk in order to solve the
complex problem of tolerance in the patient as safely as possible.
This problem is all the more difficult since the administration of
contrast agents is often repeated during diagnostic examinations
and/or for the guiding and monitoring of the efficacy of a
therapeutic treatment.
[0004] Several approaches for improving the tolerance of complexes
of chelates with gadolinium are described in the prior art.
[0005] More than twenty years ago (U.S. Pat. No. 5,876,695), those
skilled in the art were working on formulations consisting of the
addition to a lanthanide-complexing chelate of an amount of chelate
in excess, i.e. chelate non-complexed by the lanthanide. This
excess chelate is intended to compensate for an undesired release
of lanthanide, the excess chelate then complexing with the released
lanthanide (Gd.sup.3+ metal ion).
[0006] In U.S. Pat. No. 5,876,695 the chelates (ligands L) added in
excess for macrocyclic chelates are described under the form of an
excipient having the formula X[X',L], where X and X' are metal ions
(especially calcium, sodium, zinc or magnesium) and L is the
chelate in excess. These excipients are designed to scavenge free
lanthanide.
[0007] For instance for the chelate DOTA, an excipient is
Na2[Ca-DOTA]: the DOTA chelate in excess is complexed by the
calcium ion Ca2+ in the cage formed by the chelate, with a
resulting charge 2+ to be neutralised by two Na+ ions.
[0008] A few years later, an improvement of these excipients
X[X',L] was presented in the patent EP 454 078 (U.S. Pat. No.
7,385,041) with improved X[X',L] where both X and X' are calcium or
zinc, these excipients being able even at low dosage (0,1% mol/mol)
to scavenge both free lanthanide and free organic ligand chelate.
This document covers these excipients, in particular for example
the calcium salts of calcium chelated complex, notably
Ca[Ca-HPDO3A].sub.2 instead of Na[Ca-HPDO3A], and explains (in
detail notably column 1 lines 21-40) that a free macrocyclic ligand
L instead of such excipient X[X',L] should not be used for safety
reasons due to the toxicity of free chelate L. In particular, table
1 of U.S. Pat. No. 7,385,041 illustrates with LD50 values that free
macrocyclics chelates (HP-DO3A, DO3A, DOTA) are about at least 10
times more toxic than these macrocycles under the form X[X',L]. In
particular for DOTA, the LD50 is at least about 40 times better for
Na2[Ca-DOTA] than for free DOTA.
TABLE-US-00001 Chelate Letal dose (LD 50) mMol/Kg Free macrocyclic
HP-DO3A 0.11 chelate L (not used DO3A 0.12 as excess ligand) DOTA
0.18 Excipient X[X',L] Ca[Ca-HPDO3A].sub.2 1.3 Ca[Ca-DO3A].sub.2.
1.6 Na2 [Ca-DOTA] >7 Chelate-Gd DOTA-Gd 14 HP-DO3A-Gd 12
[0009] The formulation of the commercialised product gadoteridol
(Prohance Bracco) includes 0.1% Ca[Ca-HPDO3A].sub.2, and gadobutrol
product (Gadovist Bayer Schering) includes Na[Ca-BT DO3A]
excipient.
[0010] As a conclusion, no document of the prior art describes that
the formulation of a macrocyclic chelate administered to the
patient contains or should contain, besides the macrocyclic chelate
complexed by the lanthanide, an excess of free macrocyclic chelate
(in a specific and low range) that is under the form of a free
chelate L which was not complexed with any metal ions and in
particular that is not under the form of an excipient X[X',L]. On
the opposite the one skilled in the art was discouraged to do so
due to a risk in terms of tolerance of free macrocyclic
chelate.
[0011] It is also emphasized that in the prior art for the
macrocyclic chelate (contrarily to the invention as described
later), the dedicated excipient X[X',L] was added after the
complexation of the chelate by the lanthanide (see the numerous
examples of U.S. Pat. No. 5,876,695 and U.S. Pat. No. 7,385,041).
The complexation was realised according to the steochiometric
proportions of the chelate L (HP-DO3A for example) and lanthanide
"Ian" (Gd3+ for example). Following scheme I describes the
manufacturing process of the prior art (sp means stoechiometric
proportions):
##STR00001##
PRIOR ART
Macrocyclic Chelates
[0012] use of free macrocyclic exipient unwanted
[0013] Despite all these prior-art studies, the complex problem of
tolerance still exists, especially in situations at risk of more
pronounced tolerance for the administration of MRI contrast
products. For instance a very different approach was tested
recently as illustrated in WO 2007/106 544 with grafting onto the
chelates chemical groups intended to increase the affinity of the
chelate for the metal.
[0014] A new problem has moreover recently appeared in the matter
of tolerance, namely a pathology known as NSF (nephrologic systemic
fibrosis, or fibrogenic dermopathy, with very severe effects on
human skin), which may be at least partly correlated to the
existence of free gadolinium, i.e. non-complexed gadolinium, in the
body. This disease has led to health authorities being alerted as
regards certain categories of patients with respect to marketed
gadolinium-based contrast agents. Briefly, NSF could be associated
to the transmetallation of some lanthanide from the complex
[lanthanide-chelate] by endogenic ions such as zinc and resulting
in unwanted release of free lanthanide.
[0015] In summary, this problem of tolerance of complexes of
chelates with lanthanides remains complex and important, leading to
the research of even more safe products, and to the necessity of a
perfectly controlled rate of the different entities in the
pharmaceutical solutions.
[0016] The Applicant has worked on the specific case of macrocyclic
chelates, and has demonstrated, contrary to what was expected, the
very satisfying tolerance obtained when using an amount of excess
free macrocyclic chelate at a particular low dose range, and not
under the form of an excipient X[X',L] of the prior art.
[0017] The Applicant has shown that with macrocyclic chelates, and
in particular DOTA, results are very advantageous, using a very low
excess of free chelate L, so that the pharmaceutical composition
administered to the patient contains more specifically between
0.02% and 0.4% and in particular between 0.025% and 0.25% of the
free macrocyclic chelate L.
[0018] For the purposes of the present invention hereafter, the
term "free macrocyclic chelate" means any macrocyclic chelate L not
complexed with lanthanide or with other metal ions, and in
particular not under the form of an excipient X[X',L] in which X
and X' are as described above.
[0019] Briefly the formulation selected by the Applicant with free
macrocycle has the strong advantage, notably in view of the NSF, of
increasing highly the scavenging capacity of potential free
gadolinium, as compared to the prior excipients X[X',L], as
explained further in detail in the application.
[0020] Consequently, in view of this low amount of free excess, a
new problem arises, which is unknown in the prior art, namely the
need for extremely precise and delicate industrial-scale control of
the concentrations of free macrocyclic chelate and thus of the
manufacture of the product to arrive at this range of target values
of amount of free chelate, these values needing to be stable,
including after storage for several months or years.
[0021] Specifically, taking into account the production volumes,
which are of the order of several tens of tons of active principle,
the Applicant had to develop a new and particularly optimised
preparation process that makes it possible to ensure the
reliability and reproducibility of the composition of
commercialized batches.
[0022] In particular, the Applicant found that the mixing of
stoichiometric amounts on the basis of the theoretical calculation
does not sufficiently satisfactorily give at the industrial scale
the respective amounts of complex of chelate with the lanthanide
and of free chelate in low concentration in the pharmaceutical
formulation. The reason for this is that it is then necessary to
perform several analysis steps, which takes several hours, and
significantly increases the industrial cost price of the product.
In contrast, the Applicant's process makes it possible especially
to prepare beforehand and to optimize the analytical device, which
is important as regards its impact on the quality of the final
product.
[0023] More specifically, by respecting the stoichiometric
proportions and by adding an excess of DOTA intended not to be
complexed with the lanthanide, it is not possible at the industrial
scale to achieve sufficiently reproducibly in the final
pharmaceutical solution an excess of free DOTA in the target range,
especially given: [0024] 1) the uncertainty of weighing at the
industrial scale, which does not make it possible to correctly
ensure the ratio (of the order of 1000) between the chelate and the
excess chelate, given the small amount of excess chelate; [0025] 2)
the variability of the hygroscopic characteristics of the chelate
(associated with its acid functions).
[0026] It is pointed out, specifically, that to prepare an
industrial amount, typically, for example 200 litres of a 0.5 M
solution of gadolinium chelate (for example DOTA-Gd), the amount of
DOTA to be added in excess after complexation of the DOTA with the
lanthanide, to obtain an excess of free DOTA of 0.1 mol/mol %,
would be about 40 g of DOTA in 200 litres of the DOTA solution (40
g in addition to the 40 kg of DOTA initially placed in solution),
which does not allow sufficiently reliable reproducibility at the
industrial level.
[0027] This problem has been solved by the Applicant by means of
using at least one step of measuring in the liquid pharmaceutical
formulation concentrations of free macrocyclic chelate (C.sub.ch 1)
and/or of free lanthanide (C.sub.lan 1) and at least one step of
adjusting the C.sub.ch1 and/or the C.sub.lan 1 so as to obtain the
desired concentration of Ca.sub.ch 1 and C.sub.lan 1=0,
advantageously by modifying the amounts of macrocyclic chelate or
of lanthanide in the pharmaceutical composition.
[0028] C.sub.ch 1 abbreviation refers to the concentration of free
chelate.
[0029] C.sub.lan 1 abbreviation refers to the concentration of free
lanthanide.
[0030] Throughout the application, the equality C.sub.lan 1=0 is
used to define that C.sub.lan 1 in the formulation injected into
the patient is zero or substantially zero (typically less than
10.sup.-10 M and advantageously less than 10.sup.-12 M or
10.sup.-14 M), the possible presence in solution of an extremely
small amount of lanthanide not being able to be totally excluded.
The reason for this is that concentrations less than 10.sup.-10 M
cannot be measured sufficiently reliably by the current analytical
methods.
[0031] Thus, according to one aspect, the present invention relates
to a process for preparing a liquid pharmaceutical formulation of
complex of macrocyclic chelate with lanthanide, the said process
comprising at least one step of measuring in the liquid
pharmaceutical formulation concentrations of free macrocyclic
chelate (C.sub.ch 1) and/or of free lanthanide (C.sub.lan 1) and at
least one step of adjusting the C.sub.ch 1 and/or the C.sub.lan 1,
so as to obtain (sufficiently stably in the final pharmaceutical
solution, i.e. the pharmaceutical formulation intended to be
administered to the patient) a mol/mol amount of free macrocyclic
chelate of between 0.002% and 0.4%, advantageously between 0.02%
and 0.3% and very advantageously between 0.025% and 0.25%.
[0032] The present invention thus relates to a process for
preparing a liquid pharmaceutical formulation containing a complex
of macrocyclic chelate with a lanthanide and a mol/mol amount of
free macrocyclic chelate of between 0.002% and 0.4%, advantageously
between 0.02% and 0.3% and very advantageously between 0.025% and
0.25%, the macrocyclic chelate advantageously being chosen from
DOTA, NOTA, DOTAGA, DO3A, BT-DO3A (gadobutrol), HP-DO3A and PCTA,
and is advantageously DOTA, the said process comprising the
following successive steps: [0033] b) preparation of a liquid
pharmaceutical composition containing, firstly, the complex of
macrocyclic chelate, with a lanthanide, and, secondly, free
macrocyclic chelate, advantageously that is not under the form of
an excipient X[X',L] in which L is the macrocyclic chelate and X
and X' are a metal ion, in particular chosen independently from
calcium, sodium, zinc and magnesium, and/or free lanthanide; [0034]
c) measurement in the pharmaceutical formulation obtained in step
b) of the concentration of free macrocyclic chelate C.sub.ch 1
and/or of free lanthanide C.sub.lan 1; [0035] d) adjustment of
C.sub.ch 1 and/or of C.sub.lan 1 so as to obtain C.sub.ch 1=C.sub.t
ch 1 and C.sub.lan 1=0, wherein C.sub.t ch 1 is the target
concentration of the free macrocyclic chelate in the final liquid
pharmaceutical formulation. [0036] Advantageously, the process
according to the present invention comprises a prior step a) of
determination of the theoretical target concentration of free
macrocyclic chelate C.sub.t ch 1 in the final liquid pharmaceutical
formulation.
[0037] The reaction is represented as follows as Scheme II (with
"L" the ligand chelate, and "lan" the lanthanide gadolinium Gd3+
for example):
##STR00002##
[0038] The reaction is in two steps:
[0039] Step 1:
[0040]
[L].sub.initial+[lan].sub.initial-->[L-lan].sub.initial+[L].sub.-
free or [lan].sub.free
[0041] with the concentration C.sub.ch 1 of [L] and the
concentration C.sub.lan 1 of [lan].sub.free being measured
[0042] Step 2:
[0043] [L-lan].sub.initial+[L].sub.free or
[lan].sub.free+[L].sub.adjustment or
[lan].sub.adjustment-->[L-lan]+[L].sub.target free
[0044] with the concentration C.sub.ch 1.sup.=C.sub.t ch 1 of [L]
.sub.target free and C.sub.lan 1=0 of [lan].sub.free
[0045] For the purposes of the present invention, the term "amount
of free macrocyclic chelate" means the proportion of free
macrocyclic chelate relative to the amount of complexed macrocyclic
chelate (gadoteric acid in the case of DOTA-Gd) present in the
formulation in mol/mol. In the rest of the description, it will be
referred to without preference as the "amount of free macrocyclic
chelate" or the "excess free macrocyclic chelate". And as mentioned
before, macrocyclic chelate L is not under the form of an excipient
X[X',L] and is not complexed with any metal ion (namely X and
X').
[0046] For the purposes of the present invention, the term "free
lanthanide" means any lanthanide not complexed with a macrocyclic
chelate.
[0047] It is recalled herein that in document U.S. Pat. No.
5,876,695 for the linear DTPA chelate, in Example 2, the amounts of
excess chelate are defined from the start on the calculated basis
of the stoichiometry, and without a step of prior adjustment or
measurement of the concentrations. More specifically, in the said
example, 0.5 mol of DTPA and 0.25 mol of gadolinium oxide
(Gd.sub.2O.sub.3) are mixed in accordance with the stoichiometric
proportions, and a 0.1 mol/mol % (0.5 mmol) excess of ligand is
added; for macrocyclic chelates this does not ensure the target
amount of ligand desired by the Applicant in the case of a
large-scale industrial manufacture.
[0048] It is precised that the use of an excess of free linear
ligand DTPA is destinated to scavenge free lanthanide that would
otherwise be liberated during the conservation time of the
formulation.
[0049] The adjustment process of the invention for macrocyclics is
advantageously destinated to make absolutely sure (in particular
due to the quantities used and to the detection limited capacities
of the available analytical tools) that the level of free entities
is totally controlled, and in particular that there is no free
gadolinium in the manufactured pharmaceutical solution. This
adjustment method is particularly advantageous for the industrial
complexation issued from the mixture of the chelate and the
lanthanide in solution.
[0050] It is also reminded that, as know by the one skilled in the
art, the process of adjustment of the Applicant would not be
applicable at the industrial scale with an excipient X[X',L] in
view of the thermodynamic and kinetic equilibrium of such
excipient, except maybe if further very complex methods were used
(the manufacturer would have to manage both the metal ions and the
lanthanide kinetic and thermodynamic constants).
[0051] As device for analysis/assay of the free macrocyclic
chelate, any suitable equipment is used. Advantageously, a
potentiometer or capillary electrophoresis is used for the
macrocyclic chelate. More specifically, in the presence of copper
sulfate, the free DOTA contained in the solution obtained from the
complexation step (in bulk) complexes the copper. The excess copper
sulfate is assayed in preferably pH 5 buffered medium, by
potentiometry, with a solution of EDTA in the presence of a
copper-indicating electrode and a reference electrode.
[0052] The analysis/assay of the free lanthanide is performed by
using, for example, a solution of EDTA in the presence of xylenol
orange Arsenezo as turning-point indicator. Free gadolinium is
assayed advantageously with a colorimetric method using 0.01 M
edetate disodium titration solution in the presence of xylenol
orange as indicator. Titration is carried out in pH=5 sodium
acetate/acetic acid buffered solution on 20 mL of DOTAREM product
until the indicator turns colour from red to yellow. 0.1 ml of 0.01
M edetate disodium solution corresponds to 0.0008% weight/volume of
free Gd (8 ppm). The method is valid from 8 to 100 ppm of free
gadolinium
[0053] To the knowledge of the Applicant colorimetric methods are
well known but it was neither known nor suggested to use them for
the measure of gadolinium Gd3+ in contrast agents at the very low
levels of the present invention, which is of strong interest for
the adjustment process of the invention and belongs to the same
inventive concept. As such the invention also relates according to
another aspect to an analytical method of measuring free lanthanide
at the low range of the application and consisting in a
colorimetric method (also called potentiometric method).
[0054] The present invention concerns an analytical colorimetric
method for measuring the level of free lanthanide in a liquid
pharmaceutical formulation containing a complex of macrocyclic
chelate with a lanthanide and a mol/mol amount of free macrocyclic
chelate of between 0.002% and 0.4%.
[0055] In order to perform step d), several solutions are possible
as a function of the C.sub.lan 1 and C.sub.ch 1 measured in step
c).
[0056] In particular, the following solutions are concerned: [0057]
if C.sub.lan 1>0 and/or C.sub.ch 1<C.sub.t ch 1, the
adjustment may advantageously be performed by adding free
macrocyclic chelate and/or by eliminating free lanthanide and/or by
modifying the pH as described herein below; [0058] if C.sub.lan 1=0
and C.sub.ch 1>C.sub.t ch 1, the adjustment may advantageously
be performed by eliminating free macrocyclic chelate and/or by
adding free lanthanide and/or by modifying the pH as described
hereinbelow.
[0059] In the situation of an elimination of free lanthanide,
[lan].sub.adjustment of Scheme 2 means that free lanthanide lan is
eliminated.
[0060] In the situation of an elimination of free chelate,
[L].sub.adjustment of Scheme 2 means that free chelate L is
eliminated.
[0061] Advantageously, the elimination of free lanthanide is
performed by passing through an ion-exchange resin. It is thus
possible, for example, to use a resin of styrene/divinylbenzene
copolymers which contains iminodiacetate ions acting as chelating
group for the binding with the metal ions (Gd.sup.3+ in
particular).
[0062] Advantageously, the elimination of free macrocyclic chelate
is performed, for example, by filtration, advantageously using
resins (for example anionic resins).
[0063] In one particular embodiment, step b) consists in mixing a
solution of free macrocyclic chelate (initial) and of free
lanthanide (initial) so as to obtain complexation of the lanthanide
by the macrocyclic chelate, advantageously by adding the lanthanide
(preferably solid lanthanide) into the solution of free macrocyclic
chelate. It is emphasized that the prior art did not suggest that
the optimisation of the complexation (so as to reach the target
quantity of free excess ligand) would require the adjustment method
of the Applicant.
[0064] The lanthanide is advantageously added in the form of oxide
(gadolinium oxide in particular), but the invention also covers
other possible forms of lanthanide, especially the lanthanide salts
known to those skilled in the art.
[0065] The precise experimental conditions of step b) are detailed
in the examples. Advantageously, the temperature for step b) is
between 60 and 100.degree. C., and is advantageously about
80.degree. C. Advantageously, the pharmaceutical formulation is
then cooled before the adjustment step d). The duration of step b)
is, for example, from 1 hour to 3 hours.
[0066] Moreover, throughout the description hereinabove and
hereinbelow of the adjustment variants of step d), it is understood
that the complexation step b) may be performed in several sub-steps
which would be equivalent to an overall complexation step. The
complexation may be performed, for example, by preparing about half
the final volume of the tank, and then adding gadolinium oxide at
acidic pH.
[0067] It is possible to use a preparation process such that:
[0068] in step b), the amounts of free macrocyclic chelate
(initial) and of free lanthanide (initial) added are equal to the
stoichiometric proportions; [0069] step c) consists in measuring
C.sub.ch1 and/or C.sub.lan 1 ; [0070] step d) consists in adding to
the formulation obtained in step b) the amount of free macrocyclic
chelate necessary, firstly, to complete, if necessary the
complexation of the free lanthanide and to obtain C.sub.lan 1=0 (or
substantially equal to 0), and, secondly, to obtain C.sub.ch
1=C.sub.t ch 1.
[0071] For the purposes of the present invention, the expression
"the amounts of free macrocyclic chelate and of free lanthanide
added are equal to the stoichiometric proportions" means that the
amounts added are such that, in the light of the stoichiometry of
the complexation reaction, all the lanthanide and all the chelate
should be in complex form and there should be no free macrocyclic
chelate.
[0072] However, advantageously, it is preferred, in the process
according to the invention, for step c) of measurement of the
concentrations to be performed in a medium in which the
complexation reaction of step b) is performed: [0073] by using a
difference between the stoichiometric proportions and the amounts
of free lanthanide and of free macrocyclic chelate added in step
b), [0074] or by modifying the pH to shift the chemical equilibria
in favour or in disfavour of complexation.
[0075] For the purposes of the present invention, the expression
"difference between the stoichiometric proportions and the amounts
of free lanthanide and of free macrocyclic chelate added in step
b)" means that the amounts of free lanthanide and of free chelate
added in step b) are such that, in the light of the stoichiometry
of the complexation reaction, not all the lanthanide is complexed
by the chelate (excess lanthanide and/or deficit of chelate
relative to the stoichiometry) or not all the chelate is complexed
with the lanthanide (excess chelate and/or deficit of
lanthanide).
[0076] Advantageously, this difference is such that the macrocyclic
chelate/lanthanide or lanthanide/macrocyclic chelate mol/mol ratio
is less than or equal to 1.4, advantageously between 1.001 and 1.3,
particularly advantageously between 1.005 and 1.2, and in
particular between 1.005 and 1.02. It is also pointed out that this
ratio may be adapted depending on whether an excess of chelate or
an excess of lanthanide is used. When an excess of lanthanide is
used for the complexation, advantageously the
lanthanide/macrocyclic chelate mol/mol ratio is typically less than
or equal to 1.2. When an excess of chelate is used for the
complexation, the macrocyclic chelate/lanthanide mol/mol ratio is
advantageously less than or equal to 1.4.
[0077] Thus, in one advantageous embodiment, the amounts of free
macrocyclic chelate and of free lanthanide added are such that not
all the macrocyclic chelate is complexed with the lanthanide or
such that not all the lanthanide is complexed with the macrocyclic
chelate. Consequently, after this step b), the pharmaceutical
formulation will typically comprise macrocyclic chelate-lanthanide
complex and: [0078] either free macrocyclic chelate, [0079] or free
lanthanide.
[0080] In this case, the preparation process according to the
present invention is characterized in that, in step b), there is a
difference between the amounts of free macrocyclic chelate and of
free lanthanide added and the stoichiometric proportions, this
difference advantageously being such that the macrocyclic
chelate/lanthanide or lanthanide/macrocyclic chelate mol/mol ratio
is less than or equal to 1.4, advantageously between 1.001 and 1.3,
particularly advantageously between 1.005 and 1.2 and in particular
between 1.005 and 1.02.
[0081] According to particular embodiments, the ratio will be, for
example, 1.01, 1.02, 1.03 or 1.04. This gives, for example, the
concentrations presented in Table 1 below, which shows the case of
an excess of initial free lanthanide, given that an excess of
initial chelate may also be used.
TABLE-US-00002 Concentration of free Concentration of free
macrocyclic chelate lanthanide (initial) (1) (initial) added in
step b) added in step b) Lanthanide/chelate (M) (M) ratio 0.480
0.520 1.083 0.487 0.513 1.053 0.492 0.508 1.032 0.497 0.504 1.014
(1) this is the amount of Gd.sup.3+, and not of Gd.sub.2O.sub.3
[0082] For example, in the case of the chelate DOTA, an amount of
free chelate corresponding to a concentration of 0.497 M of chelate
and an amount of free lanthanide corresponding to a concentration
of 0.504 M of lanthanide, which corresponds to a lanthanide/DOTA
mol/mol ratio of x=1.014 (with x=0.504/0.497), will be added in
step b).
[0083] Another way of expressing this difference relative to the
stoichiometric proportions is to define it relative to the
lanthanide concentration in the final solution.
[0084] In the case of this example which illustrates an excess of
lanthanide, the difference is 0.6%=100*[(0.5-0.497)/0.5)], for a
formulation at 0.5 M of gadolinium at stoichiometry. The difference
is thus, for example, advantageously between 0.1 mol % and 2 mol %
of the concentration at stoichiometry of the pharmaceutical
formulation.
[0085] In one embodiment that is also advantageous (preferred mode)
the adjustment step d) is performed without touching the total
amount of lanthanide present in the formulation, i.e. without
adding or removing any lanthanide. In this case, only the total
amount of macrocyclic chelate and/or the pH is modified.
[0086] For the purposes of the present invention, the term "total
amount of lanthanide" means all the lanthanide present in free form
and in complexed form.
[0087] For the purposes of the present invention, the term "total
amount of macrocyclic chelate" means all the macrocyclic chelate
present in free form and in complexed form.
[0088] Thus, in a first case (case A of the preferred mode), an
excess of lanthanide relative to the macrocyclic chelate is added
in step b); and step d) consists in adding free macrocyclic
chelate.
[0089] In this case, the preparation process according to the
present invention is characterized in that: [0090] in step b), the
amounts of free macrocyclic chelate and of free lanthanide added
are such that not all the lanthanide is complexed, the
lanthanide/macrocyclic chelate ratio (mol/mol) advantageously being
less than 1.2; [0091] step c) consists in solely measuring of
C.sub.lan 1 , Ca.sub.ch 1 typically being equal to 0 (or
substantially equal to 0); [0092] step d) consists in adding to the
formulation obtained in step b) the amount of free macrocyclic
chelate necessary, firstly, to complete the complexation of the
free lanthanide so as to obtain C.sub.lan 1=0 and, secondly, to
obtain an excess of free macrocyclic chelate C.sub.ch1=C.sub.t ch
1.
[0093] In a second case (case B of the preferred mode), an excess
of macrocyclic chelate relative to the lanthanide is added in step
b). In this case, depending on the excess of chelate, step d)
consists in adding or removing macrocyclic chelate.
[0094] Specifically, when the excess chelate added in step b) makes
it possible to obtain C.sub.ch 1<C.sub.t ch 1, it is then
appropriate in step d) to add further free macrocyclic chelate in
order to obtain C.sub.ch1=C.sub.t ch 1.
[0095] On the other hand, if the excess chelate added in step b)
makes it possible to obtain C.sub.ch 1>C.sub.t ch 1, it is then
appropriate in step d) to remove free macrocyclic chelate (where
appropriate, to add free Gd) in order to obtain C.sub.ch1=C.sub.t
ch 1.
[0096] In this latter case, the preparation process according to
the present invention is characterized in that: [0097] in step b),
the amounts of free macrocyclic chelate and free lanthanide added
are such that all the lanthanide is complexed and that C.sub.ch
1>C.sub.t ch 1, the macrocyclic chelate/lanthanide ratio
(mol/mol) advantageously being less than 1, 2; [0098] step c)
consists in solely measuring C.sub.ch 1, C.sub.lan 1 being equal to
0; [0099] step d) consists in removing the appropriate amount of
free macrocyclic chelate so as to obtain C.sub.ch 1=C.sub.t ch
1.
[0100] It is pointed out that, in cases A) and B), as illustrated
in the detailed Example 2, the adjustment step d) comprises at the
end a step of adjustment of the pH and of the volume,
advantageously with meglumine for DOTA.
[0101] In a third case (case C) the pH of the formulation (and
optionally other functionally equivalent chemical parameters) is
controlled so as to shift the reaction equilibrium in order to
obtain at the end the target pharmaceutical solutions (excess
amount of target ligand).
[0102] According to one embodiment, the preparation process is such
that: [0103] in step b), the amounts of free macrocyclic chelate
and of free lanthanide added are equal to the stoichiometric
proportions; [0104] it comprises between steps b) and c) an
intermediate step b1) of modifying the pH of the pharmaceutical
formulation obtained in step b) so as to shift the chemical
equilibria in favour or in disfavour of complexation; [0105] step
c) is performed on the formulation obtained in step b1); [0106]
step d) consists in adjusting C.sub.ch 1 and/or C.sub.lan 1 so as
to obtain C.sub.ch 1=C.sub.t ch 1 and C.sub.lan 1=0 (or
substantially 0) by modifying the pH so as to shift the equilibrium
in the direction opposite to that of step (b1) and optionally by
adding or removing free macrocyclic chelate.
[0107] For example, the process according to the invention is
characterized in that: [0108] in step b), the mixing is performed
at a pH of between 4 and 7, advantageously between 5 and 6.5,
[0109] step b1) consists in increasing the pH using a base up to a
value of between 10 and 13 and advantageously between 11 and 12,
[0110] step d) consists in lowering the pH down to a value of
between 6.5 and 7.5 and advantageously between 6.8 and 7.4, and
optionally adding or removing free macrocyclic chelate.
[0111] For example, the complexation is performed at a pH below 6
(for example between 3 and 6 and advantageously between 5 and 6)
and the pH is then raised, for example, to about 12 (for example
with NaOH), and the pH is then adjusted to about 7.
[0112] In variants of the process without pH adjustment, as
described in the detailed Example 2 of the present patent
application, in step 2, the complexation is typically performed at
a pH below 6 (for example between 3 and 6), the pH being brought
directly to about 7. Without going into the complex mechanisms, it
is indicated that, given the thermodynamic constants varying
according to the pH, step b1) of the process with pH adjustment is
such that it makes it possible to achieve the target range of
excess free chelate in the pharmaceutical solution at least up to
the expiry of the shelf life of the pharmaceutical solution.
Increasing the pH makes it possible to shift the equilibrium in the
direction from an excess of macrocyclic chelate to a level
substantially equal to the target excess amount. Next, by reducing
the pH, a reduction at a very low rate in the amount of free
macrocyclic chelate is obtained such that, over the shelf life of
the product, the amount of free lanthanide/macrocyclic chelate does
not change unfavourably. This would result from the implied
thermodynamic constants associated with the pH modifications.
[0113] It may also be pointed out that when the free lanthanide
measurement will be performed (at pH 7), the concentration will be
lower than if the pH change had not been made, and the adjustment
is then made with the correct amount of chelate.
[0114] Furthermore, without going into the detail of the
complexation mechanisms that take place at the molecular level in
several phases (described especially in Chem. Eur. J., 2004, 10,
5218-5232), the Applicant points out that it was not at all obvious
that the process with adjustment would make it possible to obtain
this result.
[0115] In another advantageous embodiment, step b) consists in
preparing a solid complex [chelate-lanthanide] and in dissolving it
(in water).
[0116] In this case, step d) is performed on a liquid formulation
obtained by dissolving a solid [chelate-lanthanide] complex.
[0117] According to this embodiment, step b) of the process
according to the invention comprises two sub-steps: [0118] i) the
preparation of a solid complex [chelate-lanthanide] and [0119] ii)
the dissolution of the complex obtained in step i).
[0120] The adjustment in step d) may be performed as described
previously in detail (addition of chelate or of lanthanide, removal
of chelate or of lanthanide, adjustment by pH modification).
[0121] The preparation of the solid complex, which is
advantageously crystalline [chelate-lanthanide], involves, where
appropriate, at least one treatment step (filtration,
concentration, crystallization, drying, spraying, etc.) for
obtaining the appropriate physicochemical characteristics,
especially in terms of solubility and purity.
[0122] As a conclusion, the manufacturing methods of the Applicant
allow the optimized control of the proper range of free ligand
excess, which is important for the clinicians. In vivo the
scavenging capacity towards free gadolinium is presumably much
higher for free ligand (DOTA for instance) than for excipient
X[X',L] (sodium salt of DOTA-Ca for instance). Taking the example
of DOTA as macrocyclic chelate, considering that the kinetic of
complexation/uncomplexation of an excipient X[X',DOTA] is much less
that of free DOTA, this excipient would liberate the DOTA only
slowly and/or a little in physiological situation, as compared to
the free DOTA. Thus free DOTA of the formulation of the applicant
is, as regards to free Gd complexing, significantly more available
than the DOTA of the excipient X[X',DOTA], notably in case of an
accumulation of complex in a biological compartment. As a result,
free DOTA excess is highly much better than excipient X[X',DOTA]
for avoiding the transmetallation due to free gadolinum in
vivo.
[0123] It is precised that this is different from the case of
linear chelates (DTPA-BMA notably), for which the excipient X[X',L]
is used because this excipient uncomplexes very quickly (or leads
to quick transmetallation) and thus can scavenge free Gd. This
effect of excipient X[X',L] for linear chelates has been recently
demonstrated in vivo on human skin NSF patients and this excipient
is added in high quantity (5 to 10% mol/mol).
[0124] In addition, in another particularly advantageous
embodiment, a further technical problem was solved by the Applicant
for the industrial manufacture of a pharmaceutical formulation of
contrast agent based on a macrocyclic chelate-lanthanide complex,
while at the same time making it possible to maximize the tolerance
profile of the contrast product. More specifically, contrary to the
prior-art teaching, for example U.S. Pat. No. 5,082,649 (excess of
free calcium of 1 to 25%) which completes U.S. Pat. No. 5,876,695
(which uses large quantities of calcium chelate) in the
pharmaceutical formulation, the Applicant has demonstrated that, in
the case of the process according to the present invention, a very
low amount of calcium would make it possible to ensure the
industrial control of this process and to obtain a very
well-tolerated product.
[0125] More specifically, the reliability of step c) of measuring
the amounts of chelate and/or of lanthanide with common industrial
analytical tools is markedly improved when the amount of calcium in
the components used (in particular in the macrocyclic chelate, the
lanthanide and the water used in step b)) is less than a very low
target value of around 15 to 200 ppm. The amount of calcium
(quantity of calcium) in the macrocyclic chelate used in step b) is
advantageously less than 200 ppm and advantageously in the region
of or less than 50 ppm and even preferably less than 15 ppm. For
example, if the amount of calcium in the DOTA [active principle in
the form of powder supplemented with water in step b)--see the
detailed Example 2--dissolution step 1] is too high (and especially
greater than 200 ppm), calcium may complex the chelate and the
adjustment of the amount of free chelate will not be performed
sufficiently satisfactorily.
[0126] The low amount of calcium in the pharmaceutical solution
makes it possible to avoid possible disadvantageous interferences
regarding the assays of free macrocyclic chelate (for example by
complexing the calcium with the chelate) and thus to obtain an
assay of the free chelate and its adjustment in a manner that is
particularly effective for manufacture at the industrial scale at
the required high level of quality. Furthermore, a very low calcium
concentration controlled in the final product administered to the
patient (especially the meglumine salt of gadolinium DOTA) is
advantageous as regards the calcaemia of the patients in so far as
it makes it possible to avoid any homeostasis imbalance: the impact
of the injected product (typically at a dose of less than 20 ml) on
the calcaemia is at most in the region of 0.5%. The amount of
calcium in the administered contrast product is advantageously less
than 50 ppm and especially less than 20 ppm, for example between 1
and 5 ppm. For example, for the meglumine salt of gadolinium DOTA,
a limit of 15 .mu.g of Ca/g of DOTA powder (15 ppm) used in step b)
corresponds to 3 .mu.g Ca/ml of liquid contrast product
administered to the patient (there is about 0.202 g of DOTA per ml
of administered liquid contrast product), i.e. 3 ppm in this
contrast product.
[0127] The different variants of the process according to the
invention as described previously thus advantageously comprise,
before the measuring and adjustment steps c) and d), an
intermediate step b2) of controlling the amount of calcium in the
formulations obtained in step b).
[0128] Where appropriate, in particular if the amount of calcium in
the final solution is greater than 15 ppm or advantageously greater
than 10 ppm, this intermediate step comprises, following this
control, the removal of the excess calcium.
[0129] Thus, according to one aspect, the process according to the
present invention is characterized in that the amount of calcium in
the liquid pharmaceutical formulation administered to the patient
is less than 50 ppm, especially less than 20 ppm, and preferably
less than 5 ppm, the process advantageously comprising, before step
c), an intermediate step b2) of measuring the amount of calcium
and, where appropriate, of removing the excess calcium.
[0130] Furthermore, the different variants of the process according
to the invention as described previously advantageously comprise,
before step b), control of the amount of calcium in the components
used in step b), and especially in the macrocyclic chelate intended
to be dissolved, in the lanthanide (typically used in oxide form),
and in the water. Advantageously, the amount of calcium in these
components is less than 150 ppm and preferably less than 15 ppm.
Thus, according to one aspect, the process according to the present
invention is characterized in that the amount of calcium in these
components (typically DOTA powder, gadolinium Gd2O3 powder, water)
is less than 150 ppm and preferably less than 15 ppm. According to
an aspect the invention concerns a DOTA as an intermediate product
(DOTA powder or DOTA in aqueous solution) containing calcium at
less than 150 ppm, preferably less than 50 ppm, and preferably less
than 15 ppm.
[0131] Very advantageously, the Applicant has succeeded in removing
the excess calcium in the chelate (powder) used in step b), by
means, in particular for DOTA, of a purification by crystallization
using a water-ethanol mixture, which makes it possible to obtain an
amount of calcium advantageously less than 50 ppm. The water used
for step b) is also advantageously purified, where appropriate by
means of a suitable treatment, for example descaling with acids to
prevent any undesired amount of calcium.
[0132] A gadolinium oxide with a purity very close to 100%,
substantially of 99.999%, will preferably be used in
particular.
[0133] Furthermore, it will be preferred to check that the
meglumine used at the end of the adjustment step d) also comprises
a small amount of calcium.
[0134] The process is also advantageously such that it uses
components that have extremely low amounts of metals (for example
nickel and aluminium) liable to interact with the chelate,
disrupting the assays. Thus, the process advantageously includes a
step of checking the amount of these metals before the measuring
and adjustment steps b) and/or c) and/or d).
[0135] Finally, the process according to the present invention also
advantageously comprises an additional step e) of checking
C.sub.ch1 and C.sub.lan1, irrespective of the variant described
above.
[0136] The process according to the present invention is, according
to one preferred embodiment, characterized in that the
pharmaceutical formulation is a pharmaceutical formulation of
meglumine salt of the DOTA-gadolinium complex.
[0137] The Applicant's process makes it possible to obtain the
target formulations safely. This process makes it possible to solve
the problem represented by the in situ complexation, in a
pharmaceutical manufacturing reactor (into which is added the
pharmaceutical formulation agent). Specifically, when the
lanthanide is Gd.sup.3+, meglumine will be used as formulation
agent. However, given the physicochemical characteristics of
gadoteric acid, the mixing of the three components (powder of
non-complexed chelate, lanthanide powder and meglumine powder) in
the same reactor would not be sufficiently satisfactory. Thus, the
process according to the invention that allows this problem to be
solved consists in engaging the complexation, measuring the
difference relative to the target, and adjusting.
[0138] Overall, the Applicant's process thus makes it possible to
incorporate the chelation process into the pharmaceutical
production, with an advantage especially in terms of cost price and
quality.
[0139] In one advantageous embodiment, an agent for blocking the
free lanthanide, other than the free macrocyclic chelate, is added
in step b). Advantageously, this blocking agent is a polycarboxylic
acid, especially a dicarboxylic, tricarboxylic or tetracarboxylic
acid, in particular a citrate or a derivative thereof.
[0140] As regards the general inventive concept of the target range
of amount of free macrocyclic chelate (0.002% to 0.4%,
advantageously 0.02% to 0.3% and in particular 0.025% to 0.25%),
the Applicant points out that this range differs from the teaching
of patent U.S. Pat. No. 5,876,695 illustrated in particular by its
examples, at least for the following reasons.
[0141] The Applicant's target range is very narrow, and corresponds
to a selection within the very broad range presented in the said
document.
[0142] The formulations described in U.S. Pat. No. 5,876,695, which
concern macrocyclic chelates (especially Examples 3 and 4), are
formulations with salts of chelate (calcium disodium, zinc disodium
DOTA) and not with free chelate. The amounts of excess salts
therein are moreover very high, at least 10%. However, in the
present patent application, only the free chelates are used, and
not in the faun of salts.
[0143] The formulations presented in U.S. Pat. No. 5,876,695, which
have an amount of free chelate of about 0.1%, concern only linear
chelates (DTPA), and the DTPA formulation at 0.08% described is
clearly indicated as a control solution, the said document
suggesting, on the contrary, the use of a much higher amount, 2% or
quite probably more.
[0144] Specifically, the only test presented as regards tolerance
on the use of chelates, in Table 2 and in column 6 (lines 62-67) of
the said document, shows that the reduction in toxicity is markedly
less favourable for an amount of linear free chelate of 0.08
mol/mol % (Formulation A for which the amount is established on the
basis of the ratio between 0.5 mmol Gd DTPA and 0.0004 mmol
DTPA/kg), in comparison with the 2% amount corresponding to the
advantageous formulation (Formulation B for which the amount
established on the basis of the ratio between 0.5 mmol Gd DTPA and
0.01 mmol DTPA/kg) and which is described as a low value (column 6,
line 61).
[0145] The Applicant thus worked on formulations with an amount of
free macrocyclic chelate about 5 to 100 times lower than that
explicitly recommended by document U.S. Pat. No. 5,876,695. It was
thus demonstrated by the Applicant, surprisingly, that macrocyclic
chelates, and more especially DOTA, behave differently from linear
chelates such as DTPA as regards tolerance, resulting from the
presence of an excess of free chelate.
[0146] More specifically, whereas the tolerance appears to be
improved with DTPA by increasing the excess free chelate from 0.08%
to 2%, the tolerance degrades, in contrast, for DOTA by increasing
the excess free chelate, passing from very low values (0.025% to
0.25%) to a value of 2%. Consequently, the transposition of values
to reduce the risk of toxicity, between a linear chelate (in
particular DTPA), and macrocyclic chelates (in particular DOTA), is
not at all obvious. This is moreover what is illustrated by the
current complex discussions in the scientific community in the
context of NSFs with regard to the tens of millions of doses of
contrast agents already injected in man, discussions on the subject
of the complexation kinetics and/or on comparisons of structures
between chelates. For instance it has recently been shown that in
order to reduce the risk of NSF (results on human skin where
gadolinium accumulates) for some linear chelates, it is highly
recommended to use very high quantities of excipient X,X'L for
linear chelates, namely about 5 to 10% of such excipient, and that
free chelate such as DTPA-BMA should clearly not be used.
[0147] To this end, according to another aspect, the invention
relates to a pharmaceutical formulation that may be obtained via
the process according to the present invention, characterized in
that it contains between 0.002 and 0.4 mol/mol %, more especially
between 0.02 and 0.3 mol/mol % and very advantageously between
0.025 and 0.25 mol/mol %, of free macrocyclic chelate,
advantageously of free DOTA.
[0148] By virtue of the adopted selection of the range of excess
free macrocyclic chelate, in particular of free DOTA, a value of
free lanthanide in solution, and in particular of gadolinium, of
about from 10.sup.-10 M to 10.sup.-14 M at physiological pH, is
obtained.
[0149] The concentration of complexed chelate in the formulation is
typically between 1 .mu.M and 1 M, with an administered dose of
about from 0.01 to 5 mmol/kg. The concentration of the injected
formulation is typically about 0.5 M.
[0150] The process particularly advantageously relates to the
preparation of the pharmaceutical formulation of the meglumine salt
of the DOTA-gadolinium complex: the macrocyclic chelate and the
free macrocyclic chelate are DOTA, the lanthanide is gadolinium,
and the prepared salt is the meglumine salt.
[0151] Advantageously, the pharmaceutical formulation according to
the present invention is characterized in that the macrocyclic
chelate is DOTA and in that the formulation contains between 0.02
and 0.08 mol/mol % of free DOTA.
[0152] This lower range is liable to have several physiological
advantages: [0153] limiting a risk of chelation for certain
diseases of endogenous cations (for example zinc or copper) by the
presence of an overly large excess of macrocyclic chelate, [0154]
limiting the inhibition of metalloenzymes, especially ACE, with an
impact on the regulation of arterial hypertension, for example,
[0155] avoiding unfavourable medicinal interactions with metallic
active principles:
[0156] lithium, bismuth, platinum, etc., [0157] avoiding disrupting
the seric dosages of endogenous metals, [0158] avoiding medicinal
interactions with active principles that are complexing, for
example detoxifying (deferroxamine, cyclam, etc.).
[0159] In another advantageous embodiment, the pharmaceutical
formulation according to the present invention is characterized in
that the macrocyclic chelate is DOTA and in that the formulation
contains between 0.15 and 0.25 mol/mol % of an excess amount of
free DOTA.
[0160] This higher range is liable to have several physiological
advantages: [0161] optimally limiting the amount of free gadolinium
injected, the free gadolinium being a toxicity risk and possibly
being involved in phagocytosis mechanisms associated with certain
diseases, [0162] minimizing the in vivo transmetallation in
pathological situations, especially transmetallation by iron
(increase in seric iron).
[0163] This higher range is also an advantage for further improving
the stability of the formulation to be injected over time
(dechelation under unsuitable storage conditions: heat,
depressurization in aircraft, excessive exposure to light,
etc.).
[0164] According to one embodiment, the amount of free macrocyclic
chelate is between 0.09% and 0.15%. This median range is liable to
combine advantages of the lower and higher ranges.
[0165] The choice of the amount of free macrocyclic chelate may be
optimized in particular as a function of the risk of the patients
for various pathologies or pathological risks associated with the
mechanisms presented hereinabove. For example, in the case of
patients presenting a risk of NSF, an excess of macrocyclic chelate
in the median or high range may be preferred, to minimize any
release of gadolinium.
[0166] Very low values of excess free chelate are, however, also
liable to have a beneficial effect in the pathology NSF if it turns
out in certain categories of patients (kidney failure patients in
particular) that this pathology is partly associated with a
presence of free chelate, which would involve in vivo
transmetallation or similar phenomena that are unfavourable in
terms of tolerance.
[0167] According to another aspect, the calcium content of the
pharmaceutical formulation (administered to the patient) according
to the invention is less than 50 ppm, advantageously less than 30
ppm and advantageously less than 15 ppm.
[0168] According to another aspect, the invention relates to use of
a contrast product formulation, the said formulation comprising a
complex of macrocyclic chelate with a paramagnetic metal ion and an
amount of free macrocyclic chelate of between 0.025% and 0.25%,
advantageously of a formulation according to the present invention,
for improvement of the tolerance.
[0169] According to another aspect, the invention relates to a
method for improving the in vivo tolerance of an MRI contrast
product based on macrocyclic chelate, and more especially on DOTA,
which consists in using an excess of free chelate in an amount of
between 0.025 and 0.25 mol/mol %, especially 0.025-0.08%,
0.09-0.15%, 0.16-0.25%.
[0170] Advantageously, the concentration of chelate (complexed
chelate) in the formulation is between 0.5 and 0.9 M.
[0171] The macrocyclic chelate that is useful in the context of the
present invention is advantageously chosen from the following
chelates: DOTA, NOTA, DO3A, BT-DO3A, HPDO3A, PCTA, DOTAGA and
derivatives thereof; and is most particularly DOTA. The chemical
formulae of these chelates are widely known to those skilled in the
art, and are recalled, for example, in WO 2007/042 504, on pages 20
to 23, and WO 2003/011115, on pages 8 to 11.
[0172] The invention also relates to the use of a pharmaceutical
formulation according to the invention for the preparation of a
diagnostic composition for medical imaging, or for diagnostic
monitoring of the efficacy of a therapeutic treatment, and to a
diagnostic method comprising the administration of a
pharmaceutically acceptable amount of a formulation according to
the invention.
[0173] For diagnosis in MRI, the intravenous administration by
injection usually as a saline solution is typically performed at a
dose of from 1 to 500 .mu.mol Gd/kg. The pharmaceutically
acceptable unit doses will depend on the nature of the chelate, the
route of administration, and on the patient and especially on the
nature of the disorder to be studied. For an intravenous injection
and observation by magnetic resonance, the concentration of the
solution will typically be between 0.001 and 0.5 mol/litre, and
from 0.001 to 0.1 millimol/kg will be administered to the patient,
depending on the case. Higher clinical doses may also be practised,
for example a triple dose (0.3 millimol/kg). The administration
rate, the concentration, the speed of injection are adapted
according to the clinical indication and product specifications,
and eventually also in view of the behavior of the contrast agent
during the MRI procedure. Any appropriate protocol is used, with
possible adjustment of the administration in view of the patient
data, of first test injections operated, of the enhancement curves
obtained. The speed of injection may be calculated (advantageously
automatically by data treatment tools) according to the protocol
and during the protocol in view of the relaxivity curve during the
course of the acquisition; for instance if the administration
rate/speed is not sufficient for optimal enhancement considering
the data base, the injector automatically increases this rate
during the MRI procedure.
[0174] Among the advantageous diagnostic indications, mention will
be made of the indications already used clinically, and the
indications for which the results are improved by virtue of the
formulations according to the invention. Mention will thus be made
of the following indications and improvements thereof: angiography,
cerebral imaging, vascular imaging, imaging of cardiovascular,
cancer, neurodegenerative and inflammatory pathologies, any
indication with perfusion imaging, any indication combining the use
of several contrast products, especially MRI, X-ray scanner, SPECT,
PET, PET CT, and any indication with successive administrations of
contrast products at the same or at different concentrations, or in
multimodal imaging. According to embodiments, these novel
formulations may be chosen to be administered in combination with
or in place of prior-art formulations as a function of the
diagnostic profile of the patient, and especially of the profile of
tolerance of the patient to the contrast products. The choice may
be made by the practician and/or automatically by any tagging
system (RFID tag carried by the patient, . . . ) and conditioning
the type of administration, for example the choice of the contrast
agent best adapted such as the formulation of the present
application.
[0175] An installation comprising a device for evaluating the
tolerance of the patient, and a device like an injector for
administering the formulation of the contrast product as a function
of the result given by the evaluation device may thus be used.
Several risks may be evaluated, especially the risk of NSF
(nephrogenic fibrosis). Where appropriate, the MRI product is
co-administered simultaneously with or subsequently to at least one
anti-NSF therapeutic agent (anti-fibrosis agent known
therapeutically, especially steroids, anti-inflammatories or
vitamins, for example).
[0176] Where appropriate, an evaluation of the patient's risk with
respect to NSF is performed to optimize the dose/concentration of
injected contrast product (for example, the dose may be reduced
relative to the common clinical dose, if it makes it possible,
while avoiding any risk, to obtain sufficiently satisfactory
information to obtain the signal in imaging).
[0177] To further reduce the risk of toxicity of the lanthanide in
the case of at-risk patients, the Applicant also studied
formulations comprising: [0178] as in the prior art: the chelate of
lanthanide (for example gadoteric acid DOTA-Gd complex or a linear
Gd-chelate) and the salification agent for neutralizing the
chelate, for example meglumine (organic base), [0179] but in
addition with at least one biocompatible supplementary excess
blocking agent, intended to block any lanthanide (Gd.sup.3+) that
might otherwise remain free in the formulation.
[0180] Among the blocking agents that will especially be used are
organic anions such as monocarboxylic or polycarboxylic acids
(advantageously tricarboxylic or tetracarboxylic, such as citrate
and derivatives thereof), hydroxy acids (lactate, malate . . . ),
or other agents capable of an advantageous coordination interaction
with the lanthanide.
[0181] The blocking agent may thus be introduced into the
formulation and/or co-administered to the patient.
DETAILED EXAMPLES
[0182] 1) Example 1: In Vivo Tolerance
[0183] The tolerance results in Table 2 (acute toxicity in mice for
a diagnostic solution of DOTA; this solution is a pharmaceutical
solution injected and comprising the complex of DOTA with the Gd3+,
and an excess of free DOTA not complexed by Gd3+ and not complexed
by metal ions as excipient) show that formulations containing from
0.025 to 0.25 mot/mol % of free macrocyclic chelate DOTA are three
times less toxic than the formulation close to 2%.
TABLE-US-00003 Excess of Free DOTA Male LD.sub.50 Female LD.sub.50
Test mol/mol % Mmol/kg Mmol/kg 1 0.05 12.41 13.59 2 0.09 13.06
13.50 3 0.25 12.02 12.07 4 1.98 4.80 4.80
[0184] Further stability studies performed by the Applicant show
that the formulations are very satisfying with no release of
gadoninium for a long conservation time.
[0185] Example 2: Process for Preparing Formulations of Lanthanide
Chelate (Mixture of a Solution of Chelate and of a Solution of
Lanthanide)
[0186] The preparation of formulations in which the macrocyclic
chelate is DOTA is more specifically described. Table 3 below gives
an example of the amounts used for the manufacture of a solution of
100 litres of DOTA (industrial amount).
TABLE-US-00004 Component Amount DOTA (1) 20.100 kg (i.e. 0.497M)
Gadolinium oxide (expressed as 9.135 kg (i.e. 0.504M) anhydrous
product) Meglumine (expressed as anhydrous 9.215 kg product)
Solution for adjusting DOTA to 5% qs 15-35 mg per 100 ml amount of
free DOTA 3N meglumine solution qs pH = 6.8-7.4 at 20.degree. C.
Injection-grade water qs 100 litres (1)
1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid
[0187] Step 1: dissolution
[0188] 40 litres of injection-grade water at 80.degree. C. are
placed in a 100-litre manufacturing tank, the injection of nitrogen
is started, and the 20.100 kg of DOTA and the 9.135 kg of
gadolinium oxide are then incorporated with stirring. The
complexation is performed at a pH below 6, for example between 3
and 6, for example at pH 4. The gadolinium oxide in the presence of
DOTA forms a water-soluble acid complex.
[0189] Step 2: measurements
[0190] After step 1, a sample is taken and the free gadolinium is
assayed.
[0191] Step 3: adjustment of the free species
[0192] The adjustment of the solution is advantageously performed
with gadolinium oxide or DOTA.
[0193] A DOTA-adjusting solution is thus added qs an amount of
15-35 mg per 100 ml.
[0194] Step 4: cooling
[0195] The final solution from step 3 is cooled to 30.degree. C.,
for example by circulating cold water in the tank jacket.
[0196] Step 5: adjustment of the pH and of the mass per unit
volume
[0197] The acid function of the complex formed is salified with
meglumine and the pH at 20.degree. C. is adjusted to 6.8-7.4. The
concentration is adjusted by adding injection-grade water.
[0198] The following are thus introduced into the manufacturing
tank: [0199] 9.125 kg of meglumine [0200] and a solution of
meglumine pH=6.8-7.4 at 3N [0201] injection-grade water, qs.
[0202] The final solution is then filtered and then placed in
bottles typically sterilized by autoclaving.
[0203] 2) Example 3: Process for Preparing Formulations of
Lanthanide Chelate (Dissolution of a Solid Complex
[Chelate-Lanthanide])
##STR00003##
[0204] This example illustrates the manufacture of a small amount
of product, the appropriate transposition being performed at the
industrial scale.
TABLE-US-00005 Int. 1 Int. 2 (Gd.sub.2O.sub.3) Int. 3 M.sub.w (g
mol.sup.-1) 404.42 362.70 580.63 m (g) 10 4.48 n (mol) 0.025 (1 Eq)
0.0125 (0.5 Eq)
[0205] 10 g (0.025 mol; 1 eq) of macrocyclic chelate DOTA are
dissolved in 200 ml of water by heating to 80.degree. C., in a
three-necked flask equipped with a condenser, a thermometer and a
pH meter. The measured pH is 3.7. It is adjusted to 6 with 2N NaOH
solution. 4.48 g (0.0125 mol; 0.5 eq) of gadolinium oxide are
added. The pH is readjusted and kept stable at between 6 and 7 by
adding 1N HCl. The reaction is left at 80.degree. C. with
stirring.
[0206] The residual free gadolinium is removed by means of a chelex
resin prerinsed with water. To do this, the reaction mixture is
brought to pH 5 (the resin is more efficient). The whole is left
for 2 hours with stirring at room temperature. The pH rises to
between 6.5 and 7. The resin is removed by filtration.
[0207] The complex is precipitated in ethanol to remove the salts
(5 volumes of EtOH per 1 volume of water).
[0208] An assay of the salts is performed by titration with a 0.05N
silver nitrate solution.
[0209] Quantification of the free gadolinium is also performed by
colorimetric assay with Arsenazo (III). 11.5 g of product are
obtained (white powder). Yield=80%; HPLC purity: 98%; LC/MS
(ES.sup.4 mode): z=1 (m/z=559).
[0210] The dissolution in water is then performed via suitable
methods, for example using a water at 45.degree. C., with stirring
for about 30 minutes, and with adjustment of the pH.
[0211] The invention covers broadly other embodiments deriving from
the ones presented in detail. For instance the meglumine is added
to a solution of DOTA and afterwards gadolinium is added for the
step of DOTA complexation by gadolinium.
* * * * *